FrancophonIA/ELRC3.0 huggingface dataset:
English: The use of this veterinary medicinal product is not recommended during pregnancy.
Slovenian: Uporaba ni priporočljiva v obdobju brejosti.
English: Cardboard box of one vial of 50 doses.
Slovenian: Kartonasta škatla z eno vialo s 50 odmerki.
English: Personal protective equipment consisting of protective disposable gloves and safety glasses should be worn when handling the veterinary medicinal product.
Slovenian: Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Pri rokovanju z zdravilom nosite osebno zaščitno opremo, ki sestoji iz zaščitnih rokavic za enkratno uporabo in varnostnih očal.
English: (F4ac).............1.3 x10
Slovenian: 1.............1,3 x 10
English: Live non-pathogenic vaccine to reduce diarrhoea, faecal shedding and intestinal colonization associated with F4-positive enterotoxigenic Escherichia coli in pigs.
Slovenian: Živo nepatogeno cepivo za zmanjševanje driske, fekalnega razsejanja in črevesne kolonizacije, povezane z enterotoksigeno, za F4 pozitivno okužbo z Escherichia coli pri prašičih.
English: White or whitish lyophilisate for oral suspension.
Slovenian: Bel do belkast liofilizat za peroralno suspenzijo.
English: Coliprotec F4 lyophilisate for oral suspension for pigs.
Slovenian: Coliprotec F4 liofilizat za peroralno suspenzijo za prašiče.
English: Coliprotec F4 lyophilisate for oral suspension for pigs
Slovenian: Coliprotec F4 liofilizat za peroralno suspenzijo za prašiče
English: The vaccine induces an intestinal immunity and a serological response against F4-positive Escherichia coli in pigs.
Slovenian: Cepivo sproži črevesno imunost in serološki odziv proti okužbi z Escherichia coli, pozitivni za F4, pri prašičih.
English: CFU 2/dose not attenuated
Slovenian: 2/odmerek neatenuirano k.e.
English: Each dose of vaccine contains: Live non-pathogenic Escherichia coli O8:K87 (F4ac)
Slovenian: En odmerek cepiva vsebuje: Živ nepatogeni sev Escherichia coli O8:K87 (F4ac)
English: Lyophilisate for oral suspension
Slovenian: liofilizat za peroralno suspenzijo
English: CFU/dose
Slovenian: k.e./odmerek
English: To stimulate active immunity against enterotoxigenic F4-positive Escherichia coli in pigs.
Slovenian: Za spodbujanje aktivne imunizacije prašičev proti enterotoksigeni, za F4 pozitivni okužbi z Escherichia coli.
English: PACKAGE LEAFLET: Coliprotec F4 lyophilisate for oral suspension for pigs
Slovenian: NAVODILO ZA UPORABO Coliprotec F4 liofilizat za peroralno suspenzijo za prašiče
English: Monosodium glutamate Purified water
Slovenian: 6.1 Seznam pomožnih snovi dekstran 40 000 saharoza mononatrijev glutaminat prečiščena voda
English: Live non-pathogenic Escherichia coli O8:K87
Slovenian: Živ nepatogeni sev Escherichia coli O8:K87 (F4ac)
English: B.
Slovenian: k.e.
English: - reduce the colonisation of the ileum and faecal shedding of enterotoxigenic F4-positive Escherichia coli from infected pigs.
Slovenian: - zmanjšanje incidence zmerne do hude driske zaradi Escherichia coli po odstavitvi pri prašičih; - zmanjšanje kolonizacije spodnjega tankega črevesa in fekalnega razsejanja enterotoksigene, za F4 pozitivne okužbe z Escherichia coli pri okuženih prašičih.
English: The full EPAR and risk management plan summary for DuoResp Spiromax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo DuoResp Spiromax sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the European Union for DuoResp Spiromax on 28 April 2014.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom DuoResp Spiromax, veljavno po vsej Evropski uniji, odobrila 28. aprila 2014.
English: This is a summary of the European public assessment report (EPAR) for DuoResp Spiromax.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo DuoResp Spiromax.
English: DuoResp Spiromax is also used to relieve the symptoms of severe chronic obstructive pulmonary disease (COPD) in adults who have had exacerbations (flare-ups) of the disease in the past despite regular treatment.
Slovenian: Zdravilo DuoResp Spiromax se uporablja tudi za zdravljenje simptomov hude kronične obstruktivne pljučne bolezni (KOPB) pri odraslih s ponavljajočimi se poslabšanji simptomov bolezni v preteklosti kljub rednemu zdravljenju.
English: DuoResp Spiromax budesonide / formoterol
Slovenian: DuoResp Spiromax budezonid/formoterol
English: This means that it is similar to a ‘reference medicine' containing the same active substances, but DuoResp Spiromax is given using a different inhaler.
Slovenian: To pomeni, da je podobno referenčnemu zdravilu, ki vsebuje isti zdravilni učinkovini, vendar se zdravilo DuoResp Spiromax uporablja z drugačnim inhalatorjem.
English: A risk management plan has been developed to ensure that DuoResp Spiromax is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila DuoResp Spiromax je bil pripravljen načrt obvladovanja tveganj.
English: What measures are being taken to ensure the safe and effective use of DuoResp Spiromax?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila DuoResp Spiromax?
English: Because DuoResp Spiromax is a hybrid medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo DuoResp Spiromax generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
English: The company initially also applied for a lower strength of DuoResp Spiromax, however bioequivalence to the reference product was not demonstrated and the application for this strength was withdrawn.
Slovenian: Prvotno je družba predložila tudi vlogo za manjšo jakost zdravila DuoResp Spiromax, vendar biološka enakovrednost z referenčnim zdravilom ni bila dokazana, zato je bila vloga za to jakost umaknjena.
English: The two active substances in DuoResp Spiromax are well known and are present in several medicines used to treat asthma and COPD, either alone or in combination with other medicines.
Slovenian: Zdravilni učinkovini v zdravilu DuoResp Spiromax sta dobro znani in sta prisotni v več zdravilih, ki se samostojno ali v kombinaciji z drugimi zdravili uporabljajo za zdravljenje astme in KOPB.
English: For more information about treatment with DuoResp Spiromax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom DuoResp Spiromax preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What are the benefits and risks of DuoResp Spiromax?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom DuoResp Spiromax?
English: As asthma reliever therapy, patients can take 1 or 2 additional inhalations of DuoResp Spiromax 160/4.5 microgram only to relieve their symptoms.
Slovenian: Pri olajševalnem zdravljenju astme lahko bolniki uporabijo 1 ali 2 dodatna vpiha zdravila DuoResp Spiromax 160/4,5 mikrogramov, vendar samo za lajšanje simptomov.
English: The higher strength, DuoResp Spiromax 320/9 microgram (320 micrograms of budesonide and 9 micrograms of formoterol), can only be used for the regular treatment of asthma and for the treatment of COPD.
Slovenian: Večja jakost zdravila DuoResp Spiromax 320/9 mikrogramov (320 mikrogramov budezonida in 9 mikrogramov formoterola) se sme uporabljati samo za redno zdravljenje astme in zdravljenje KOPB.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for DuoResp Spiromax, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila DuoResp Spiromax in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that DuoResp Spiromax 160/4.5 microgram and 320/9 microgram have been shown to have comparable quality and to be bioequivalent to the corresponding strengths of Symbicort Turbohaler.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da ima zdravilo DuoResp Spiromax v jakostih 160/4,5 mikrogramov in 320/9 mikrogramov primerljivo raven kakovosti kot zdravilo Symbicort Turbohaler ter da mu je biološko enakovredno pri ustrezajočih jakostih.
English: The reference medicine for DuoResp Spiromax is Symbicort Turbohaler.
Slovenian: Referenčno zdravilo za zdravilo DuoResp Spiromax je Symbicort Turbohaler.
English: Other information about DuoResp Spiromax
Slovenian: Druge informacije o zdravilu DuoResp Spiromax
English: For practical information about using DuoResp Spiromax, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila DuoResp Spiromax naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: DuoResp Spiromax is a medicine that contains the active substances budesonide and formoterol.
Slovenian: DuoResp Spiromax je zdravilo, ki vsebuje zdravilni učinkovini budezonid in formoterol.
English: It is not intended to provide practical advice on how to use DuoResp Spiromax.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: DuoResp Spiromax is a ‘hybrid medicine'.
Slovenian: DuoResp Spiromax je hibridno zdravilo.
English: What is DuoResp Spiromax and what is it used for?
Slovenian: Kaj je zdravilo DuoResp Spiromax in za kaj se uporablja?
English: 160/4.5 microgram (160 micrograms of budesonide and 4.5 micrograms of formoterol) can be used for the regular treatment of asthma and when needed as a reliever.
Slovenian: Zdravilo DuoResp Spiromax 160/4,5 mikrogramov (160 mikrogramov budezonida in 4,5 mikrograma formoterola) se lahko uporablja za redno zdravljenje astme in po potrebi tudi za olajševalno zdravljenje.
English: The Committee recommended that DuoResp Spiromax be given marketing authorisation.
Slovenian: Priporočil je, da se za zdravilo DuoResp Spiromax izda dovoljenje za promet.
English: Why is DuoResp Spiromax approved?
Slovenian: Zakaj je bilo zdravilo DuoResp Spiromax odobreno?
English: Studies in patients have been limited to tests to determine that DuoResp Spiromax is bioequivalent to the reference medicine, Symbicort Turbohaler.
Slovenian: Ker je zdravilo DuoResp Spiromax generično zdravilo, so bile študije pri bolnikih omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Symbicort Turbohaler.
English: How has DuoResp Spiromax been studied?
Slovenian: Kako je bilo zdravilo DuoResp Spiromax raziskano?
English: How does DuoResp Spiromax work?
Slovenian: Kako zdravilo DuoResp Spiromax deluje?
English: How is DuoResp Spiromax used?
Slovenian: Kako se zdravilo DuoResp Spiromax uporablja?
English: (Invented) name Strength Pharmaceutical Form Route of Administration
Slovenian: Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina vsebina velikost pakiranja
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States
Slovenian: Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikov dovoljenja za promet z zdravilom v državah članicah
English: GlaxoSmithKline 100, route de Versailles78163 Marly-le-Roi Cedex FRANCE
Slovenian: Laboratoire GlaxoSmithKline 100, route de Versailles78163 Marly-le-Roi Cedex FRANCE
English: Intravenous Use and Intramuscular use (Only one MA for 250 mg strength)
Slovenian: Zinnat intravenska uporaba in intramuskularna uporaba (samo ena odločba za 250 mg jakost)
English: 1.5g/VIAL
Slovenian: 1,5g /VIALO
English: GlaxoWellcome Farmacêutica Lda Rua Dr António Loureiro Borges nº3
Slovenian: Rua Dr António Loureiro Borges nº3
English: Glaxo Smith Kline B.V. Huis ter Heideweg 62 3705 LZ ZEIST NETHERLANDS
Slovenian: Huis ter Heideweg 62 3705 LZ ZEIST NETHERLANDS
English: GlaxoSmithKline S.p.A.Via A. Fleming, 237135 Verona ITALY
Slovenian: - Via A. Fleming, 237135 Verona
English: 1.5g/15ml 1.5g/50-100ml 1.5g (Monovial)
Slovenian: 1,5g/15ml 1,5g/50-100ml 1,5g (monoviala)
English: 250mg 2ml (intravenous) 250mg/1ml (intramuscular)
Slovenian: 250mg/2ml (intravensko) 250mg/1ml (intramuskularno)
English: Zinacef 1500mg prašek za raztopino za injiciranje ali infundiranje
Slovenian: Zinacef 1500mg prašek za raztopino za injiciranje ali infundiranje prašek za raztopino za injiciranje ali infundiranje
English: Nykaer 68, 2605 Broendby DENMARK
Slovenian: GlaxoSmithKline Pharma A/S Nykaer 68, 2605 Broendby DENMARK
English: 250mg/1ml or 250mg/2-5ml
Slovenian: 250mg/1ml ali 250mg /2-5ml
English: SLOVENIA
Slovenian: Slovenija
English: 750mg/6ml (intravenous) 750mg/3ml (intramuscular)
Slovenian: 750mg/6ml (intravensko) 750mg/3ml (intramuskularno)
English: Zinacef 750 mg 750mg Powder for Injection Intramuscular Use
Slovenian: Zinacef 750 mg 750mg prašek za raztopino za injiciranje
English: ENGLAND
Slovenian: UNITED KINGDOM
English: Curoxim 500mg
Slovenian: Curoxim 1,5g
English: Glaxo Wellcome House Berkeley Avenue Greenford
Slovenian: Glaxo Operations UK Limited Glaxo Wellcome House Berkeley Avenue Greenford
English: 750mg/3ml or 750 mg/6 - 10 ml
Slovenian: 750mg/3ml ali 750mg/6 - 10ml
English: Powder for suspension for Injection
Slovenian: prašek za suspenzijo za injiciranje
English: Curocef 250 mgTrockenstechamupll en
Slovenian: Curocef 250 mgTrockenstecha mupllen intramuskularna uporaba ali intravenska uporaba
English: Intravenous or Intramuscular Use
Slovenian: intravenska ali intramuskularna uporaba
English: GlaxoSmithKline Pharma A/S
Slovenian: GlaxoSmithKline s.a. / n.v.
English: 1.5g Powder for Infusion Intravenous Use 1.5g/15ml + 50ml or 100 ml
Slovenian: Curocef 1500 mgTrockensubsta nz zur Infusionsbereit ung intravenska uporaba 1,5g/15ml + 50ml ali 100ml
English: Intravenous Use/ Intramuscular Use
Slovenian: intravenska uporaba/ intramuskularna uporaba
English: Intravenous use, intramuscular use
Slovenian: intravenska uporaba, intramuskularna uporaba
English: Powder for suspension for Infusion
Slovenian: prašek za suspenzijo za infundiranje
English: Glaxo Group Ltd., Glaxo Welcome House, Berkeley avenue, Greenford, Middlesex UB6 0NN
Slovenian: Glaxo Group Ltd., Glaxo Welcome House, Berkeley avenue, Greenford, Middlesex UB6 0NN ENGLAND
English: Glaxo Group LtdGlaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN UNITED KINGDOM
Slovenian: Glaxo Group Ltd, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN UNITED KINGDOM
English: GlaxoSmithKline s.a. / n.v. Rue du Tilleul 13
Slovenian: Rue du Tilleul 13
English: Injection : 1.5g/15ml Infusion : 1.5g/15ml + 50ml or 100ml
Slovenian: Curocef 1500 mgTrockenstecha mpullen prašek za raztopino za injiciranje ali infundiranje injekcija : 1,5g/15ml infuzija : 1,5g/15ml + 50ml ali 100ml
English: Powder for suspension for injection or solution for injection and infusion
Slovenian: prašek za suspenzijo za injiciranje ali raztopino za injiciranje in infundiranje intramuskularna uporaba, intravenska uporaba
English: Powder for solution for injection and infusion
Slovenian: prašek za raztopino za injiciranje in infundiranje
English: Powder for solution/ suspension for injection/infusion
Slovenian: prašek za raztopino/ suspenzijo za injiciranje/ infundiranje
English: Curocef 750 mgTrockenstechampull en
Slovenian: Curocef 750 mgTrockenstecha mpullen intramuskularna uporaba ali intravenska uporaba
English: Intravenous Use and Intramuscular use
Slovenian: intravenska uporaba in intramuskularna uporaba
English: Zinacef 750 mg prašek za raztopino za injiciranje ali infundiranje
Slovenian: Zinacef 750 mg prašek za raztopino za injiciranje ali infundiranje prašek za raztopino za injiciranje ali infundiranje intramuskularna uporaba/ intravenska uporaba
English: Powder for Solution /Suspension for Injection
Slovenian: prašek za raztopino/ suspenzijo za injiciranje
English: 750mg Powder for Infusion Intramuscular Use
Slovenian: 750mg prašek za raztopino za infundiranje
English: 250mg Solution for injection Intravenous Use
Slovenian: intravenska uporaba intramuskularna uporaba 250mg/ VIALO
English: Powder and solvent for suspension for Injection
Slovenian: Zinnat prašek in vehikel za suspenzijo za injiciranje
English: 750mg Solution for injection Intravenous Use
Slovenian: intravenska uporaba intramuskularna uporaba 750mg /VIALO
English: 250mg + 1 x 2ml solvent
Slovenian: 250mg raztopina za injiciranje intravenska uporaba 250mg + 1 x 2ml vehikla
English: 250mg Powder for Injection Intramuscular Use
Slovenian: Curoxim 250mg prašek in vehikel za suspenzijo za injiciranje
English: 750mg +1 x 6ml solvent
Slovenian: 750mg raztopina za injiciranje intravenska uporaba 750mg +1 x 6ml vehikla
English: Powder for solution for injection or infusion
Slovenian: prašek za raztopino za injiciranje ali infundiranje
English: 1.5g Powder for Injection Intravenous Use/ Intramuscular Use
Slovenian: prašek in vehikel za raztopino za injiciranje intravenska uporaba / intramuskularna uporaba
English: Curoxim 750mg Powder for solution for Infusion
Slovenian: Curoxim 750mg prašek in vehikel za suspenzijo za injiciranje
English: 250mg Powder for Injection Intravenous Use Intramuscular Use
Slovenian: prašek za suspenzijo za injiciranje intravenska uporaba intramuskularna uporaba
English: Date of birth: {DD MMM YYYY} SEC:
Slovenian: Datum rojstva: {DD MMM LLLL} SEC:
English: June 2022
Slovenian: junij 2022
English: Key elements:
Slovenian: Bistveni elementi:
English: * Frequency is based on laboratory values.
Slovenian: * Pogostnost izhaja iz laboratorijskih vrednosti.
English: In particular, you must not be given certain vaccines called live vaccines:
Slovenian: Zlasti je pomembno, da ne prejmete določenih cepiv, ki jih imenujemo živa cepiva:
English: These other medicines may include:
Slovenian: Med temi drugimi zdravili sta lahko:
English: This can take 3 to 6 hours and may need to be repeated.
Slovenian: Ta postopek lahko traja 3 do 6 ur in ga je v nekaterih primerih treba ponoviti.
English: No alternative adequate animal models are available.
Slovenian: Drugih primernih živalskih modelov ni na voljo.
English: 9 months.
Slovenian: 9 mesecev
English: • if you are allergic to any of the ingredients of this medicine (listed in section 6).
Slovenian: • če ste alergični na katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: • You had a vaccination in the previous 6 weeks or are planning to have one in the next few months.
Slovenian: • če ste bili v predhodnih 6 tednih cepljeni ali načrtujete cepljenje v naslednjih nekaj mesecih.
English: No such risks were identified based on these studies.
Slovenian: Na osnovi teh študij niso odkrili nobenega od navedenih tveganj.
English: Reasons to delay treatment
Slovenian: Razlogi za odlog zdravljenja
English: The following information is intended for doctors only.
Slovenian: Naslednje informacije so namenjene samo zdravnikom
English: • You will be given a pregnancy test before treatment starts.
Slovenian: • Pred začetkom zdravljenja boste opravili nosečnostni test.
English: Very common: may affect more than 1 in 10 people
Slovenian: Zelo pogosti: lahko prizadenejo več kot 1 od 10 oseb
English: Patients should be monitored for neurological events.
Slovenian: Bolnike je treba opazovati glede nevroloških dogodkov.
English: Studies B2202 (N=75) + C2201 (N=111)
Slovenian: Študiji B2202 (N=75) in C2201 (N=111)
English: These patient are likely to be more vulnerable to the consequences of the adverse reactions described below and require special attention.
Slovenian: Ti bolniki so po vsej verjetnosti bolj dovzetni za posledice spodaj opisanih neželenih učinkov in potrebujejo posebno pozornost.
English: • Reduced levels of one or more blood cell types
Slovenian: • zmanjšano število ene ali več vrst krvnih celic,
English: Annual safety reports and 5-yearly interim reports
Slovenian: Poročila o poteku: letno varnostno poročilo in 5-letna vmesna poročila
English: Interference with serological testing
Slovenian: Interferenca s serološkimi testi
English: • There may be an effect on the results of some types of HIV test - ask your doctor about this.
Slovenian: • lahko pride do vpliva na rezultate nekaterih testov za določanje prisotnosti virusa HIV - o tem se lahko pozanimate pri svojem zdravniku.
English: Prolonged neutropenia has been associated with increased risk of infection.
Slovenian: Dolgotrajna nevtropenija je povezana s povečanim tveganjem za okužbe.
English: Name:
Slovenian: Ime in priimek:
English: Very common (≥1/10)
Slovenian: zelo pogosti (≥1/10)
English: Other side effects are listed below.
Slovenian: Drugi neželeni učinki so našteti spodaj.
English: • Very severe inflammation around the body (due to syndrome of immune activation)
Slovenian: • zelo hudo vnetje po celem telesu (zaradi sindroma aktivacije imunskega sistema),
English: Juvenile toxicity studies were not conducted.
Slovenian: Študij toksičnosti pri mladičih niso izvajali.
English: The majority of patients (101/111, 91%) received bridging therapy for disease stabilisation.
Slovenian: Večina bolnikov (101/111, 91 %) je prejemala premostitveno zdravljenje za stabilizacijo bolezni.
English: Included as part of the annual reports of the non-interventional PASS
Slovenian: Poročila o poteku: vključena kot del letnih poročil neintervencijske študije (PASS)
English: Race/ethnicity
Slovenian: Rasa/etnična pripadnost
English: No non-clinical reproductive safety studies were conducted as no adequate animal model is available.
Slovenian: Predkliničnih študij reproduktivne varnosti niso izvajali, ker ni na voljo primernega živalskega modela.
English: Kymriah should only be given if the result shows you are not pregnant.
Slovenian: Zdravilo Kymriah smete prejeti samo v primeru rezultata, ki kaže, da niste noseči.
English: Common (≥1/100 to <1/10)
Slovenian: pogosti (≥1/100 do <1/10)
English: • You have had a stem cell transplant in the last 4 months.
Slovenian: • če ste imeli v zadnjih 4 mesecih presaditev krvotvornih matičnih celic.
English: If these side effects become severe or serious, tell your doctor immediately.
Slovenian: Če ti neželeni učinki postanejo hudi ali resni, takoj obvestite zdravnika.
English: This is so your doctor can check if your treatment is working and help you if you have any side effects.
Slovenian: To je potrebno zato, da vaš zdravnik lahko spremlja, ali zdravljenje deluje, in vam pomaga, če pride do neželenih učinkov.
English: Therefore, leukapheresis material from these patients will not be accepted for Kymriah manufacturing.
Slovenian: Iz tega razloga levkaferezni material teh bolnikov ne bo sprejet za izdelavo zdravila Kymriah.
English: Manufacture and release of Kymriah usually takes about 3-4 weeks.
Slovenian: Izdelava in sproščanje zdravila Kymriah običajno traja 3 do 4 tedne.
English: Do not use this medicine if the infusion bag is damaged or leaking.
Slovenian: Ne uporabljajte tega zdravila, če je infuzijska vrečka poškodovana ali pušča.
English: Your doctor will regularly check your blood counts as the number of blood cells and other blood components may decrease.
Slovenian: Zdravnik bo redno pregledoval število vaših krvnih celic, ker se lahko zgodi, da se zmanjša število krvnih celic in koncentracije drugih sestavin krvi.
English: You may be given medicines to help prevent the condition.
Slovenian: Morda boste prejeli zdravila za preprečevanje tega zapleta.
English: Juvenile animal studies
Slovenian: Študije na mladičih živali
English: Repeat tocilizumab as needed at a minimum interval of 8 hours if there is no clinical improvement.
Slovenian: Odmerjanje tocilizumaba po potrebi ponovite po intervalu najmanj 8 ur, če ne pride do kliničnega izboljšanja.